LIK066



NAME OF DRUG : LIK066

ALSO KNOWN AS : LIK066

LABORATORY : NOVARTIS

STATUS AND ADVANCEMENT

Type of drug : SGLT1-SGLT2 inhibitor

Clinical trials advancement : Ongoing Phase 2a

Estimated time to market : 114 months.

LABORATORY ABSTRACT ON THE DRUG

NOT PROVIDED

HISTORY AND ANALYSIS

A Phase 2 trial NCT03205150 is starting in september 2017

Endpoints are serologic markers, no any histologic endpoint

 

TRIALS IN COURSE AND PLANNED

NCT03205150

A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH)

Estimated Enrollment: 110
Anticipated Study Start Date: September 19, 2017
Estimated Study Completion Date: August 10, 2019
Estimated Primary Completion Date: August 10, 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LIK066 Dose 1
LIK066 Dose 1 will be taken once daily before lunch for 12 weeks
Drug: LIK066
LIK066 tablets will be taken orally once daily
Experimental: LIK066 Dose 2
LIK066 Dose 2 will be taken once daily before lunch for 12 weeks.
Drug: LIK066
LIK066 tablets will be taken orally once daily
Experimental: Placebo
Placebo will be taken once daily before lunch for 12 weeks.
Drug: Placebo
Placebo tablets will be taken orally once a day

 

RECENT NEWS ON LIK066

SOME PUBLICATIONS RELATED WITH LIK066

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH LIK066


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE